![](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2017/09/main-128.jpg)
![Biotechnology company exploring novel therapeutics for neuroscience indications](https://www.pharmaceutical-technology.com/wp-content/uploads/static-progressive/nri/pharma/clients/Catalent/P&S2-lead.jpg)
An innovative biotechnology company exploring novel therapeutics for neuroscience indications had developed a promising new chemical entity for the treatment of a severe paediatric genetic disease.
However, numerous drug delivery challenges threatened the realisation of the fast-track status designation they had received due to promising early stage results.
By partnering with Catalent and leveraging our proprietary RP Scherer Softgel technology, the customer was able to overcome a number of potential hurdles and expeditiuosly enter the Phase II/III clinical trial.